Re: Clinical Outcomes in Octogenarians Treated with Docetaxel as First-Line Chemotherapy for Castration-Resistant Prostate Cancer

被引：0
作者：
Griebling, Tomas L.
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 01期
关键词：
D O I：
10.1016/j.juro.2016.10.035
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
[31]   Impact of body composition parameters on clinical outcomes in patients with metastatic castration-resistant prostate cancer treated with docetaxel [J].
Power, Derek Gerard ;
Cushen, Samantha ;
McDermott, Ray ;
Lim, Marvin Chang Jui ;
Mceneaney, Peter ;
Daly, Louise ;
Griffin, Brendan ;
Murphy, Kevin P. ;
Ryan, Aoife M. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[32]   Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer [J].
Xu, Nanwei ;
Zhao, Jinge ;
Zhao, Fengnian ;
Liu, Haoyang ;
Yin, Wenlian ;
Zhu, Sha ;
Nie, Ling ;
Sun, Guangxi ;
Zheng, Linmao ;
Liu, Zhenhua ;
Cai, Diming ;
Chen, Junru ;
Dai, Jindong ;
Ni, Yuchao ;
Wang, Zhipeng ;
Zhang, Xingming ;
Liang, Jiayu ;
Chen, Yuntian ;
Hu, Xu ;
Pan, Xiuyi ;
Yin, Xiaoxue ;
Zhu, Xudong ;
Zhang, Yaowen ;
Wang, Zilin ;
Zeng, Yuhao ;
Wang, Minghao ;
Shen, Pengfei ;
Chen, Ni ;
Zeng, Hao .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) :7247-7258
[33]   Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer [J].
Nanwei Xu ;
Jinge Zhao ;
Fengnian Zhao ;
Haoyang Liu ;
Wenlian Yin ;
Sha Zhu ;
Ling Nie ;
Guangxi Sun ;
Linmao Zheng ;
Zhenhua Liu ;
Diming Cai ;
Junru Chen ;
Jindong Dai ;
Yuchao Ni ;
Zhipeng Wang ;
Xingming Zhang ;
Jiayu Liang ;
Yuntian Chen ;
Xu Hu ;
Xiuyi Pan ;
Xiaoxue Yin ;
Xudong Zhu ;
Yaowen Zhang ;
Zilin Wang ;
Yuhao Zeng ;
Minghao Wang ;
Pengfei Shen ;
Ni Chen ;
Hao Zeng .
Journal of Cancer Research and Clinical Oncology, 2023, 149 :7247-7258
[34]   Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC) [J].
De Jager, R. L. ;
Roman, L. ;
Lopatkin, N. ;
Karlov, P. ;
Breitz, H. ;
Earhart, R. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[35]   Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel [J].
Buttigliero, C. ;
Tucci, M. ;
Vignani, F. ;
Pisano, C. ;
Bertaglia, V. ;
Pignataro, D. ;
Bironzo, P. ;
Guglielmini, P. F. ;
Scagliotti, G. V. ;
Di Maio, M. .
ANNALS OF ONCOLOGY, 2016, 27
[36]   Is chemical/surgical castration necessary during docetaxel chemotherapy for castration-resistant prostate cancer? [J].
Watanabe, Masahito ;
Kanao, Kent ;
Muramatsu, Hiroyuki ;
Morinaga, Shingo ;
Kajikawa, Keishi ;
Kobayashi, Ikuo ;
Nishikawa, Genya ;
Kato, Yoshiharu ;
Nakamura, Kogenta ;
Sumitomo, Makoto .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[37]   Overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line docetaxel-containing chemotherapy according to their participation (or not) in clinical trials. [J].
Goyal, Jatinder ;
Huang, Peng ;
Tyagi, Prachi ;
Oh, Daniel ;
Carducci, Michael Anthony ;
Eisenberger, Mario A. ;
Antonarakis, Emmanuel S. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
[38]   Re: First-Line Treatment in Senior Adults with Metastatic Castration-Resistant Prostate Cancer: A Prospective International Registry [J].
Griebling, Tomas L. .
JOURNAL OF UROLOGY, 2017, 197 (01) :157-157
[39]   Carboplatin plus weekly docetaxel as second-line chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (CRPC). [J].
Reuter, C. W. ;
Gruenwald, V. ;
Ivanyi, P. ;
Morgan, M. A. ;
Fenner, M. ;
Ganser, A. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[40]   Prostate-specific antigen testing in men with metastatic castration-resistant prostate cancer treated with docetaxel chemotherapy [J].
Tsai, Yuh-Shyan ;
Tzai, Tzong-Shin .
UROLOGICAL SCIENCE, 2015, 26 (04) :277-277
12345